Text size: A A A

Summary of Product Characteristics (SPC)

Summary of Product
Characteristics (SPC)

JETREA® (ocriplasmin) Intravitreal (IVT) Injection is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤400 µm.

Contraindications to the administration of JETREA® include: 1) hypersensitivity to the active substance or to any of the excipients (mannitol, citric acid, sodium hydroxide, water for injections); 2) Active or suspected ocular or periocular infections.

Over 600 patients have been treated with an intravitreal injection of JETREA®, with over 570 patients treated with the recommended dose of 0.125 mg.

All adverse reactions were ocular. The most commonly reported were vitreous floaters, eye pain and photopsia, as well as conjunctival hemorrhage resulting from the injection procedure. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were nonserious, mild in intensity and resolved within 2 to 3 weeks.

The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo treated patients.

Visual acuity reduced: In placebo-controlled studies, 7.7% of JETREA® patients and 1.6% of placebo patients had acute transient ≥2-line loss in Best Corrected Visual Acuity (BCVA) during the first week after injection. They were generally reversible within 2 weeks without intervention.

Click herefor the full Summary of Product Characteristics of JETREA®
Click here for the full Summary of Product Characteristics of JETREA®

Important Safety Information

Indications: JETREA® (ocriplasmin) Intravitreal (IVT) Injection is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Dosage: JETREA® (ocriplasmin) Intravitreal (IVT) Injection must be prepared and administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose.

Contraindications: JETREA® (ocriplasmin) Intravitreal (IVT) Injection is contraindicated for use with patients who are hypersensitive to ocriplasmin or to any of the excipients in JETREA® (mannitol, citric acid, sodium hydroxide and water), or with patients who have active or suspected ocular or periocular infections.

Warnings and Precautions: Post-Injection Monitoring: Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). Proper aseptic injection techniques must always be used. Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP. Other Warnings and Precautions: Administration of JETREA® to both eyes concurrently has not been studied, and is not recommended. Repeated administration of JETREA® in the same eye has not been studied, and is not recommended. There are no clinical data on the concomitant use of ocriplasmin with VEGF-inhibitors. JETREA® has not been studied in patients with large diameter macular holes (>400 microns), high myopia (>8 dioptre spherical correction or axial length >28 mm), aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions, exudative age-related macular degeneration (AMD) and vitreous haemorrhage; treatment is not recommended in these patients. The potential for lens subluxation or phacodonesis cannot be ruled out. There is limited experience in patients with non-proliferative diabetic retinopathy or in patients with a history of uveitis or significant eye trauma; caution should be exercised when treating such patients. The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion (VMA) or causing total posterior vitreous detachment (PVD) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA >1500 microns. Due to a potential increase in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk for a significant, but transient loss of visual acuity during the first week after the injection; patients should be monitored appropriately.

Interactions: No formal interaction studies have been conducted.

Undesirable Effects: In the JETREA® clinical studies, all adverse reactions were ocular. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks. The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo-controlled patients. Very common (≥1/10) adverse reactions are : vitreous floaters, eye pain, and conjunctival haemorrhage. Common (≥1/100 to <1/10) adverse reactions are : visual acuity reduced, visual impairment, vision blurred, retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, intraocular pressure increased,macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, metamorphopsia, vitreous adhesions, conjunctival oedema, eyelid oedema, vitritis, anterior chamber cell, anterior chamber flare, iritis, photopsia, conjunctival hyperaemia, ocular hyperaemia, vitreous detachment, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eye pruritus, ocular discomfort, photophobia, and chromatopsia. Uncommon (≥1/1,000 to <1/100) are : transient blindness, lens subluxation, scotoma, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, and conjunctival irritation.

Click here for the full Summary of Product Characteristics of JETREA®

Next: References

Take action with JETREA® (ocriplasmin) Intravitreal (IVT) Injection

JETREA® Cross eye JETREA® Cross eye JETREA® Cross eye

A one-time injection of JETREA® has been shown to provide early resolution of vitreomacular traction, including when associated with macular hole of diameter ≤400 µm.1

LEARN MORE

See the JETREA® difference in your practice with the Impact Calculator™

Impact Calculator® Impact Calculator® Impact Calculator®

Calculate how many patients with vitreomacular traction you can potentially treat in 1 year with the one-time injection of JETREA®.1

LEARN MORE

Learn about the impact of vitreomacular traction and macular hole on your patients

Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective

Vitreomacular traction and macular hole often result in visual impairment, particularly central vision loss.8,9

LEARN MORE

Important Safety Information

Indications: JETREA® is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Dosage: JETREA® must be prepared and administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose.

Contraindications: JETREA® is contraindicated for use with patients who are hypersensitive to ocriplasmin or to any of the excipients in JETREA® (mannitol, citric acid, sodium hydroxide and water), or with patients who have active or suspected ocular or periocular infections.

Warnings and Precautions: Post-Injection Monitoring: Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). Proper aseptic injection techniques must always be used. Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP. Other Warnings and Precautions: Administration of JETREA® to both eyes concurrently has not been studied, and is not recommended. Repeated administration of JETREA® in the same eye has not been studied, and is not recommended. There are no clinical data on the concomitant use of ocriplasmin with VEGF-inhibitors. JETREA® has not been studied in patients with large diameter macular holes (>400 microns), high myopia (>8 dioptre spherical correction or axial length >28 mm), aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions, exudative age-related macular degeneration (AMD) and vitreous haemorrhage; treatment is not recommended in these patients. The potential for lens subluxation or phacodonesis cannot be ruled out. There is limited experience in patients with non-proliferative diabetic retinopathy or in patients with a history of uveitis or significant eye trauma; caution should be exercised when treating such patients. The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion (VMA) or causing total posterior vitreous detachment (PVD) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA >1500 microns. Due to a potential increase in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk for a significant, but transient loss of visual acuity during the first week after the injection; patients should be monitored appropriately.

Interactions: No formal interaction studies have been conducted.

Undesirable Effects: In the JETREA® clinical studies, all adverse reactions were ocular. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks. The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo-controlled patients. Very common (≥1/10) adverse reactions are: vitreous floaters, eye pain, and conjunctival haemorrhage. Common (≥1/100 to <1/10) adverse reactions are: visual acuity reduced, visual impairment, vision blurred, retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, intraocular pressure increased,macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, metamorphopsia, vitreous adhesions, conjunctival oedema, eyelid oedema, vitritis, anterior chamber cell, anterior chamber flare, iritis, photopsia, conjunctival hyperaemia, ocular hyperaemia, vitreous detachment, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eye pruritus, ocular discomfort, photophobia, and chromatopsia. Uncommon (≥1/1,000 to <1/100) are: transient blindness, lens subluxation, scotoma, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, and conjunctival irritation.

Click here to review the JETREA® Summary of Product Characteristics.